story of the week
PFS of Early Interim PET–Positive Patients With Advanced-Stage Hodgkin's Lymphoma Treated With BEACOPPescalated Alone or in Combination With Rituximab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Progression-Free Survival of Early Interim PET-Positive Patients With Advanced Stage Hodgkin's Lymphoma Treated With BEACOPPescalated Alone or in Combination With Rituximab (HD18): An Open-Label, International, Randomised Phase 3 Study by the German Hodgkin Study Group
Lancet Oncol 2017 Feb 21;[EPub Ahead of Print], P Borchmann, H Haverkamp, A Lohri, U Mey, S Kreissl, R Greil, J Markova, M Feuring-Buske, J Meissner, U Dührsen, H Ostermann, U Keller, G Maschmeyer, G Kuhnert, M Dietlein, C Kobe, H Eich, C Baues, H Stein, M Fuchs, V Diehl, A EngertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.